Press Release

Freiburg, Germany / Frankfurt, Germany / Kyiv, Ukraine / Wroclaw, Poland, 22 January 2026 – EMUNO Therapeutics reached critical R&D milestones with remarkable efficiency in their fight against cancer supported by the competence and Integrated Drug Discovery (IDD) Platform of the CRO Enamine. EMUNO and Enamine entered a comprehensive collaboration in June 2025 to advance EMUNO’s small molecule programs in immuno-oncology aimed at achieving clinical impact for challenging malignancies. EMUNO’s mission is to develop medicines which modulate specific immune responses in a controlled, pathway-specific approach to treat autoimmune disorders or overcome cancer immune evasion, and to enhance human health and wellbeing. The European Union supports their small molecule immune activator program with an EIC Transition Grant from the European Innovation Council. The IMMUNOCON project aims to advance the drug candidate EMT-224 towards clinical readiness to address the urgent need for effective therapies for refractory and treatment-resistant solid tumors, commonly seen in advanced/ late-stage cancer patients.

Dresden, Germany / Frankfurt, Germany / Kyiv, Ukraine / Wroclaw, Poland, 16 January 2026 – ABX-CRO and Enamine initiated their cooperation in 2024. Since then, Enamine supports ABX-CRO with its integrated competencies in biology, chemistry, and computational sciences through its research centers in Frankfurt/Germany, Kyiv/Ukraine, and Wroclaw/Poland. The initial relationship proved to be highly productive, securing innovation in short research cycles and utilizing resources at its highest return on investment. In consequence of this success, ABX-CRO and Enamine continue to deepen their relationship for the future.

CHICAGO, Peapod Bio Inc., a leader in innovative assay development and high-throughput screening (HTS) solutions, today announced a strategic collaboration with Enamine, a global supplier of high-quality small molecule libraries. This partnership enables Peapod Bio to offer its clients fully integrated screening campaigns with access to Enamine’s world-class compound collections nearing five million compounds, accelerating hit discovery.

Enamine, a leading chemistry and R&D services company, today announced that it was a key synthetic chemistry contributor to a first-of-its-kind, open-science approach that led to the development of a promising broad-spectrum coronavirus antiviral pre-clinical candidate. Enamine’s chemistry platform delivered over 2,000 new compounds during the early stages of the programme that resulted in the discovery of pre-clinical candidate ASAP-0017445. The candidate is designed to be a direct-to-generic, globally accessible treatment ready for future coronavirus pandemics.

Enamine Ltd., a leading global provider of screening compounds, chemical building blocks, and drug discovery services, and The Institute of Cancer Research, London, have announced a new research collaboration aimed at broadening the tools available for Fragment-based Drug Discovery (FBDD).

We are pleased to announce that Enamine has joined the CACHE (Critical Assessment of Computational Hit-finding Experiments) Governing Board. Enamine has already played a central role in CACHE, serving as the primary supplier of compounds for the challenges since the very beginning.

Orogen Therapeutics, Inc., a private drug discovery company utilizing its proprietary, AI-enabled DNA encoded library (DEL) technology to identify novel chemical matter against medically and commercially attractive drug targets, Chemspace, LLC, an expert in the generation and exploration of ultra-large chemical datasets, and Enamine, Ltd., a leading worldwide provider of chemical compounds and drug discovery services, announced today a strategic collaboration to design, build, and test novel DNA-encoded libraries (DEL) leveraging Chemspace’s chemi-informatics and synthetic capabilities and Enamine’s REAL design principles, combined with Orogen’s deep DEL expertise, and proprietary AI- and DEL-enabled small molecule drug discovery capabilities.

Qanatpharma (QP), Zuse Institute Berlin (ZIB), Enamine, and Proteros biostructures today announced the launch of a research collaboration to accelerate the discovery of novel therapeutics targeting cerebral perfusion deficits associated with subarachnoid hemorrhage (SAH). The collaboration focuses on a protein target identified by QP that is involved in regulating cerebrovascular resistance in the brain—a mechanism shown to be compromised in patients with SAH.

Enamine, the leading provider of chemical compounds and drug discovery services, today announced certain reference compounds from Pfizer are now available through Enamine`s marketplace and Enamine`s integration capabilities (i.e. punchout site, hosted catalogs, and API solutions). This allows researchers to explore and purchase from the catalog of selected Pfizer-provided drugs, chemical dormants, investigational compounds, and isotope-labelled molecules with appropriate quality control.

Enamine, the leading provider of chemical compounds and drug discovery services, launches a non-profit organization - Enamine Scientific Research Institute (Enamine SRI). The Institute aims to coordinate scientists in Ukraine supporting research and innovations in chemistry, biology, computer science, and early-stage drug discovery, as well as to help students and young scientists in their development.

Enamine, the leading provider of chemical compounds and drug discovery services, and Pohang Accelerator Laboratory (PAL), a science and technology institution in South Korea, have signed a Memorandum of Understanding (MOU) to advance collaborative drug discovery efforts. The memorandum outlines a joint commitment to pursue research and development in fragment-based drug discovery and hit optimization. Both parties aim to provide a streamlined path from fragment identification to advanced leads by combining advanced screening technologies with fast-track chemical development.

Korean Chemical Society (KCS), an academic organization that promotes research and education in the field of chemistry and the chemistry profession, and Enamine, the leading provider of chemical compounds and drug discovery services, have signed a Memorandum of Understanding (MOU) to collaborate in the field of chemical science. The document outlines a shared framework for cooperation across academic and business domains. The aim of the MOU is to strengthen research and scientific exchange between the two organizations to drive progress in chemical science.

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the generation of screening libraries leveraging tools within its AI/ML platform, the Recursion OS, with Enamine's REAL Space, the world’s largest source of make-on-demand small molecules. Together, the two companies have curated 10 enriched screening libraries from over 15,000 newly synthesized compounds designed to accelerate drug discovery against the hundred most difficult to address biological areas and clinically relevant key drug targets.

Enamine, the leading provider of chemical compounds and drug discovery services, and ChemPass, a contract research organization for computational and AI-assisted software, today announced their start of strategic partnership to provide hit discovery solutions to their customers.

Enamine, Chemspace, and PharmAI Discovery GmbH (PAID) start a transformative collaboration to accelerate the advancement of theranostics through AI-driven drug discovery with emphasis on cancer diagnosis and therapy. This collaboration brings together the success of Enamine’s discovery biology and chemistry competencies, Chemspace’s expertise in ultra-large chemical space exploration for drug discovery, and PAID’s AI-powered molecular discovery platform to identify and develop promising drug candidates faster and with greater precision, both for conventional and molecular radiotherapy and radio diagnostics.

Elsevier, a global leader in information and analytics, and Enamine, a global leader in supplying small molecules and early drug discovery services, have announced a partnership to integrate Enamine's database of over 43 million make-on-demand (MADE) analog compounds into Reaxys. The integration will provide chemists with unparalleled access to a diverse array of chemical compounds for accelerated drug discovery and materials science research.

Enamine, a scientifically driven provider of chemistry and biology services with the world’s largest catalog of building blocks screening compounds, announced today performance results for Enamine Fast MADE building blocks.

Chemspace, an expert in the generation and exploration of ultra-large chemical datasets, and Enamine, a global leader in supplying small molecules and early drug discovery services, are pleased to announce an expansion of their collaboration to improve delivery times of molecules from Chemspace Freedom Space.

Chemspace, an expert in the generation and exploration of ultra-large chemical datasets, and Enamine, a global leader in supplying small molecules and early drug discovery services, are excited to announce a collaboration to unveil the real potential of Enamine’s chemistry capabilities and deliver unparalleled discovery solutions. By combining their unique strengths, both companies aim to accelerate and enhance the process of identifying and developing new active molecules.

FarmHannong, a leading company in the Korean agricultural industry, and Enamine Ltd, the world’s premier provider of chemical building blocks, screening compounds, and integrated discovery chemistry services, have announced the start of their collaboration.